



March 21, 2014

Ultragenyx to Present at the BioCentury Future Leaders in the Biotech Industry Conference

Novato, CA, March 21, 2014 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's Chief Executive Officer, will be presenting at the BioCentury Future Leaders in the Biotech Industry Conference on March 28, 2014 at 2:00pm ET at the Millennium Broadway Hotel & Conference Center in New York.

The live and archived webcast of the company presentation will be accessible from the company's website at <http://ir.ultragenyx.com/events.cfm>. The replay of the webcast will be available approximately one hour after the conclusion of the live presentation and will be available for one year.

About Ultragenyx

Ultragenyx is a development-stage biopharmaceutical company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases. Founded in 2010, the company has rapidly built a diverse portfolio of product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which there are no approved therapies.

The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx's strategy is predicated upon time and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.

For more information on Ultragenyx, please visit the company's website at www.ultragenyx.com.

CONTACT: Contact Ultragenyx Pharmaceutical Inc.

844-758-7273

For Media, Bee Nguyen

For Investors, Robert Anstey